Ranbaxy Sues Actavis To Block Generic Absorica Acne Drug

Law360, New York (October 31, 2013, 7:52 PM EDT) -- Ranbaxy Inc. launched suit in New Jersey federal court Tuesday alleging pharmaceutical giant Actavis Inc. has infringed its patent for acne drug Absorica by seeking federal approval to launch a generic version of the drug before the patent expires.

Ranbaxy, which was joined in the suit by fellow plaintiffs Cipher Pharmaceuticals Inc. and Galephar Pharmaceutical Research Inc., claims Actavis, formerly Watson Laboratories Inc., has filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to market generic versions of Absorica in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.